Clinical Trials Browser

Phase 2 × Leukemia, Lymphoid × ibrutinib × Clear all

Leukemia, Leukemia, Lymphoid, Leukemia, Lymphocytic, Chronic, B-Cell

NCT01500733 2024-09-19

PCI-32765 for Special Cases of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Phase 2 Active not recruiting

86 enrolled 10 charts

LymphoidOther hematologic neoplasm

Leukemia, Leukemia, Lymphoid, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell

NCT01109069 2020-05-27

Safety and Tolerability Study of PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia

Phase 2 Completed

199 enrolled 14 charts

LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Leukemia, Lymphoid, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Mantle-Cell

Clinical Trials

Ibrutinib lead-in Followed by Venetoclax Plus Ibrutinib in Patients With RR CLL

PCI-32765 for Special Cases of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Safety and Tolerability Study of PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia